No profile data available.
NextCure, Inc. (NXTC) is a healthcare company in the additional cancer treatment drugs industry, based in Baltimore, United States, with about 40 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$55.84 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $32.87 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
NextCure reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$32.87 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Adlai Nortye Ltd. (ANL), Genenta Science S.p.A. (GNTA), Cel-sci Corporation (CVM), TransCode Therapeutics, Inc. (RNAZ).